Abstract. The paradigm of obesity, diabetes mellitus and insulin resistance possibly plays a critical role in the pathogenesis of endometrial cancer (EC). Impaired glucose tolerance and insulin resistance may play a direct or facilitating role in the neoplastic transformation of the endometrium, whereas antidiabetic therapy, particularly with metformin, has been suggested to inhibit EC progression. We herein present the case of a patient with EC who recei�ed metformin mono-EC who recei�ed metformin monowho recei�ed metformin monotherapy due to complications after undergoing surgery. At 45 months after the introduction of metformin treatment, the patient had no complaints and continued recei�ing metformin without signs of tumor recurrence. As metformin is widely used among diabetic patients and in ongoing clinical trials in cancer patients, the aforementioned results deser�e further clinical in�estigation.
Introduction
Endometrial cancer (EC) is the third most common gynecological malignancy worldwide, after breast and cer�ical cancers (1). While insulin resistance and diabetes mellitus (DM) may facilitate the initiation and progression of EC, effecti�e DM control has been suggested to pre�ent or modulate EC (2) . Metformin is an oral insulin-sensitizing agent used as first-line therapy for type 2 DM (3). As shown in a recent re�iew, se�eral in vitro and obser�ational studies ha�e evaluated the potential benefits of metformin in the prevention or treatment of gynecological cancers (4, 5) . In vitro data ha�e demonstrated that metformin administration inhibits the growth and decreases the in�asion and metastasis of EC cell lines (6, 7) . A multi-institutional study recently demonstrated that metformin use was associated with an impro�ement in the recurrence-free and o�erall sur�i�al of patients with EC (8) . We herein describe the case of a patient with EC who was treated with metformin and remained disease-free during a long follow-up period.
Case report
A 79-year-old woman, gra�ida 1, para 0, presented with lower abdominal pain. The patient was examined in a gynecological clinic (September, 2012). Magnetic resonance imaging (MRI) re�ealed a mass sized ~4 cm in the endometrium (Fig. 1 ) and computed tomography (CT) re�ealed two 2-cm peritoneal disseminations (Fig. 2) . The carbohydrate antigen-125 le�el was 53 ng/ml (normal range, <35 ng/ml), and the carcinoembryonic antigen le�el was 8.6 ng/ml (normal range, <5.0 ng/ml). The diagnosis was endometrial adenocarcinoma. The patient had a history of type 2 DM and hypertension, but was not obese (body mass index, 23.6 kg/m 2 ). The HbA1c le�el (National Glycohemoglobin Standardization Program) was 9.1%, and the patient was treated with oral medications [sulfonylurea and dipeptidyl peptidase-4 (DPP-4) inhibitor].
The patient was referred to the Shimane Uni�ersity Hospital for treatment of the pel�ic and abdominal masses, where she underwent modified radical hysterectomy, bilateral salpingooophorectomy, pel�ic lymphadenectomy and abdominal mass resection. All identifiable masses were resected. Pathological examination re�ealed a stage IVB (International Federation of Gynecology and Obstetrics 2008), pT1aN0M1 endometrial serous adenocarcinoma.
Although adju�ant chemotherapy was planned, the postoperati�e follow-up was complicated by perforation of the digestive tract and severe inflammation of the peritoneum. To control glycemia, insulin was initially used, but it was replaced with metformin (250 mg once a day) and other oral medications (sulfonylurea and DPP-4 inhibitor) following discharge from the hospital. No further medical treatment was performed.
After being discharged from the hospital, the patient did not exhibit ele�ated le�els of tumor markers or any metastases on CT. At 45 months after the initial metformin treatment, the patient had no complaints and maintained a good quality of life, without signs of tumor progression. 
Efficacy of metformin for advanced

Discussion
The mechanism underlying the antitumor effect of metformin is considered to in�ol�e the acti�ation of adenosine monophosphate-acti�ated protein kinase and inhibition of the mammalian target of rapamycin, which reduces cell growth (9) . Metformin arrests the cell cycle of EC cells, decreases human telomerase re�erse transcriptase mRNA expression, and inhibits the phosphorylation of S6RP, resulting in the inhibition of signaling downstream of the mRNA pathway (10, 11) . Thus, in EC, cell cycle arrest by metformin has been obser�ed in vitro, and inhibition of telomerase acti�ity may be an important mechanism underlying the antitumor acti�ity of this drug (10) . Clinical e�idence on the effect of metformin on EC outcome is limited to retrospecti�e data and does not generally account for the effects of multiple co�ariates, such as pathology, stage and treatment, on clinical outcome (12) . It cannot be definiti�ely concluded that patients who recei�e metformin are less likely to succumb to EC, as metformin may also reduce mortality from other causes (e.g., complications of diabetes and cardio�ascular disease) (13) .
In the present case, adju�ant chemotherapy and radiotherapy could not be administered, but the patient remained disease-free o�er a long period of time with metformin therapy alone. The contribution of complete surgical resection to this clinical benefit cannot be ruled out. Moreover, whether this was the natural course of EC in our patient remains unclear. Despite these limitations, this clinical case suggests that metformin is potentially beneficial in the prevention or treatment of EC. This finding deserves further validation in clinical studies (14) (15) (16) . 
